Brief: Bionomics

Corporate news snapshot for Bionomics

Dec 9, 2009 – 4.45pm

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Bionomics (BNO) will conduct a phase II clinical trial of its BNC105 anti-cancer drug on 60 mesothelioma patients at up to 12 centres in Australia.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Introducing your Newsfeed

Follow the topics, people and companies that matter to you.

Fetching latest articles